Previous close | 15.60 |
Open | 15.30 |
Bid | 15.30 x 40000 |
Ask | 15.60 x 40000 |
Day's range | 15.30 - 15.30 |
52-week range | 11.90 - 18.10 |
Volume | |
Avg. volume | 28 |
Market cap | 22.986B |
Beta (5Y monthly) | 0.50 |
PE ratio (TTM) | 36.43 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.15 (0.99%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes.
Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram. This innovation means that plasma collection volume can be determined by an individual donor's height, weight and hematocrit level on the day they donate plasma.
Terumo Medical Corporation is pleased to announce the launch of its new AZUR HydroPack Peripheral Coil System in the United States. The AZUR HydroPack Coil System is a soft, universal-shaped platinum and hydrogel coil designed to find and fill empty space within the vessel. It is also the only packing coil to use proprietary designed hydrogel technology to create a gel core for mechanical occlusion, a unique feature of AZUR peripheral coils.[1] Terumo received Food and Drug Administration cleara